The role of subtypes of the opioid receptor in the anxiolytic action of chlordiazepoxide

Neuropharmacology

Volumn 37, Issue 2, 1998, Pages 223-232

  Ågmo, Anders ^a   Belzung, Catherine ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Anxiety; Benzodiazepines; Elevated plus maze; Mouse; Opioid receptors; Opioids

Indexed keywords

BARBITURIC ACID DERIVATIVE; BETA FUNALTREXAMINE; BINALTORPHIMINE; CHLORDIAZEPOXIDE; MEPROBAMATE; NALOXONAZINE; NALTRINDOLE; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BINDING AFFINITY; DRUG ANTAGONISM; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CHLORDIAZEPOXIDE; MALE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID;

EID: 0032004099     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00003-3     Document Type: Article

References (78)

1. Abercombie E.D., Keefe K.A., DiFrischia D.S., Zigmond M.J. Differential effects of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial prefrontal cortex. J. Neurochem. 52:1989;1655-1658.
2. Ågmo A., Fernández H., Picker Z. Naloxone inhibits the facilitatory effects of 8-OH-DPAT on male rat sexual behaviour. Eur. J. Pharmacol. 166:1989;115-116.
3. Ågmo A., Fernández H. Benzodiazepine receptor ligands and sexual behavior in the male rat: The role of GABAergic mechanisms. Pharmacol. Biochem. Behav. 38:1991;781-781.
4. Ågmo A., Galván A., Heredia A., Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology. 120:1995;186-194.
5. Appenzeller O., Standefer J., Appenzeller J., Atkinson R. Neurology of endurance training: V. Endorphins. Neurology. 30:1980;418-419.
6. Belzung C., Ågmo A. Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in BALB/c mice. Psychopharmacology. 132:1997;195-201.
7. Belzung C., Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 56:1994;623-628.
8. Billingsley M.L., Kubena R.K. The effects of naloxone and picrotoxin on the sedative and anticonflict effects of benzodiazepines. Life Sci. 22:1978;897-906.
9. Blake M.J., Stein E.A., Czech D.A. Drinking-induced alterations in reward pathways: an in vivo autoradiographic analysis. Brain Res. 413:1987;111-119.
10. Boone J.B. Jr., McMillen D. Differential effects of prolonged restraint stress on proenkephalin gene expression in the brainstem. Mol. Brain Res. 27:1994;290-298.
11. Brady K.T., Lydiard R.B., Ballenger J.C., Shook J., Laraia M., Fossey M. CSF opioids in panic disorder. Biol. Psychiatry. 30:1991;512-514.
12. Carlsson K.R., Seeger T.F. Interaction of opiates with dopamine receptors: receptor binding and behavioral essays. Pharmacol. Biochem. Behav. 16:1982;119-124.
13. Carmody J., Jamieson D., de Porteere R. Opioid-independent hyperalgesia induced in mice by pentobarbitone at low dosage. Naunyn-Schmiedeberg's Arch. Pharmacol. 334:1986;193-195.
14. Cohen G.A., Doze V.A., Madison D.V. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron. 9:1992;325-335.
15. Cooper S.J. Benzodiazepine-opiate antagonist interactions in relation to feeding and drinking behavior. Life Sci. 32:1983;1043-1051.
16. Cooper S.J. Benzodiazepines and appetite: recent pre-clinical advances and their clinical implications. Hum. Psychopharmacol. 4:1989;81-89.
17. Cruz A.P.M., Frei F., Graeff F.G. Ethopharmaological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
18. Dawson G.R., Crawford S.P., Collinson N., Iversen S.D., Tricklebank M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology. 118:1995;316-323.
19. DeRossett S.E., Holzman S.G. Effects of opiate antagonists and putative κ agonists on unpunished and punished operant behavior in the rat. Psychopharmacology. 86:1985;386-391.
20. Dienstbier R.A., Crabbe J., Johnson G.O., Thorland W., Jorgensen J.A., Sadar M.M., LaVelle D.C. Exercise and stress tolerance. Sacks M.H., Sachs M.L. Psychology of Running. 1981;192-210 Human Kinetics Publishers, Campaign, IL.
21. Dingledine R., Iversen L.L., Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur. J. Pharmacol. 47:1978;19-27.
22. Donzanti B.A., Althaus J.S. Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res. Comm. Chem. Pathol. Pharmacol. 78:1992;193-210.
23. Dourish C.T., Hutson P.H., Kennett G.A., Curzon G. 8-OH-DPAT-induced hyperphagia: Its neural basis and possible therapeutic relevance. Appetite. 7:1986;127-140.
24. Duka T., Cumin R., Haefely W., Herz A. Naloxone blocks the effect of diazepam and meprobamate on conflict behaviour in rats. Pharmacol. Biochem. Behav. 15:1981;115-117.
25. Duka T., Wüster M., Herz A. Benzodiazepines modulate striatal enkephalin levels via a GABAergic mechanism. Life Sci. 26:1980;771-776.
26. Duka T., Wüster M., Herz A. Rapid changes in enkephalin levels in rat striatum and hypothalamus induced by diazepam. Naunyn-Schmiedeberg's Arch. Pharmacol. 309:1979;1-5.
27. Duka T., Millan M.J., Ulsamer B., Doenicke A. Naloxone attenuates the anxiolytic action of diazepam in man. Life Sci. 31:1982;1833-1836.
28. Endoh T., Matsuura H., Tanaka C., Nagase H. Nor-binaltorphimine: A potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch. Int. Pharmacodyn. Ther. 316:1992;30-42.
29. File S.E. Chlordiazepoxide-induced ataxia, muscle relaxation and sedation in the rat: effects of muscimol, picrotoxin and naloxone. Pharmacol. Biochem. Behav. 17:1982;1165-1170.
30. File S.E., Zangrossi H. Jr., Andrews N. Social interaction and elevated plus-maze tests: changes in release and uptake of 5-HT and GABA. Neuropharmacology. 32:1993;217-221.
31. Finlay J.M., Zigmond M.J., Abercombie E.D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience. 64:1995;619-628.
32. Fletcher P.J. Opiate antagonists inhibit feeding induced by 8-OH-DPAT: possible mediation in the nucleus accumbens. Brain Res. 560:1991;260-267.
33. Friedman S.B., Ader R., Grota L.J. Plasma corticosterone response to parameters of electric shock in the rat. Psychosom. Med. 29:1967;323-328.
34. Goldinger A., Müller W.E., Wollert U. Inhibition if glycine and GABA receptor binding by several opiate agonists and antagonists. Gen. Pharmacol. 12:1981;477-479.
35. 3H]-flunitrazepam binding. Neuroreport. 4:1993;987-990.
36. 3H]flunitrazepam binding. Neuroreport. 5:1993;252-254.
37. Gray J.A. The Neuropsychology of Anxiety: An Inquiry into the Function of the Septo-Hippocampal System. 1982;Oxford University Press, Oxford.
38. 5-enkephalin elicited by depolarization. J. Pharmacol. Exp. Ther. 220:1982;616-620.
39. Hayes A.G., Skingle M., Tyers M.B. Reversal by β-funaltrexamine of the antinociceptive effect of opioid agonists in the rat. Br. J. Pharmacol. 88:1986;867-872.
40. Heidbreder C., Goldberg S.R., Shippenberg T.S. Inhibition of cocaine-induced sensitization by the δ-opioid receptor antagonist naltrindole. Eur. J. Pharmacol. 243:1993;123-127.
41. Hennig J., Laschefski U., Opper C. Biopsychological changes after bungee-jumping: β-endorphin immunoreactivity as a mediator of euphoria? Neuropsychobiology. 29:1994;28-32.
42. Koob G.F., Strecker R.E., Bloom F.E. Effects of naloxone on the anticonflict properties of alcohol and chlordiazepoxide. Subst. Alcohol Actions/Misuse. 1:1980;447-457.
43. Larsen P.J., Mau S.E. Effect of acute stress on the expression of hypothalamic messenger ribonucleic acids encoding the endogenous opioid precursors preproenkephalin A and proopiomelanocortin. Peptides. 15:1994;783-790.
44. Levin A.S., Morley J.E., Gosnell B.A., Billington C.J., Bartness T.J. Opioids and consummatory behavior. Brain Res. Bull. 14:1985;663-672.
45. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
46. A/benzodiazepine receptor heterogeneity. J. Psychiat. Res. 29:1995;77-94.
47. Manzanares J., Kookingland K.J., Moore K.E. Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J. Pharmacol. Exp. Ther. 256:1991;500-505.
48. Marsden, C.A., Wright, I.K., Beckett, S.G., Fulford, A., Rex, A., 1992. Animal models of anxiety: involvement of serotonin. J. Psychopharmacol. Abstr. Book A2.
49. 1A receptors in membranes from rat brain. Neuropharmacology. 30:1991;323-327.
50. McCubbin J.A. Stress and endogenous opioids: behavioral and circulatory interactions. Biol. Psychol. 35:1993;91-122.
51. McMillan D.E., Leander J.D. Drugs and punished responding. V. Effects of drugs on responding suppressed by response-dependent and response-independent electric shock. Arch. Int. Pharmacol. 213:1975;22-27.
52. Miczek K.A., Thompson M.L. Analgesia resulting from defeat in social confrontation: the role of endogenous opioids in the brain. Bandler R. Modulation of Sensorimotor Activity During Alterations in Behavioral States. 1984;431-456 Alan R. Liss, New York.
53. Negus S.S., Pasternak G.W., Koob G.F., Weinger M.B. Antagonist effects of β-funaltrexamine and naloxonazine on alfentanil-induced anti-nociception and muscle rigidity in the rat. J. Pharmacol. Exp. Ther. 264:1993;739-745.
54. 5-enkephalin on hippocampal pyramidal cells and interneurons. Neuropharmacology. 28:1989;1175-1181.
55. Passarelli F., Costa T. Mu and delta opioid receptors inhibit serotonin release in rat hippocampus. J. Pharmacol. Exp. Ther. 248:1989;299-305.
56. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
57. Pollard G.T., Howard J.L. Effects of drugs on punished behavior: pre-clinical tests for anxiolytics. Pharmacol. Ther. 45:1990;401-424.
58. Porthogese P.S., Larson D.L., Sayre L.M., Fries D.S., Takemori A.E. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonist and reversible agonistic activities. J. Med. Chem. 23:1980;233-234.
59. Privette T.H., Terrian D.M. Kappa opioid agonists produce anxiolytic-like behaviors on the elevated plus-maze. Psychopharmacology. 118:1995;444-450.
60. Rodrìguez, C., Rojas, J., Ågmo, A., 1993. The facilitatory effects of lisuride on male rat sexual behavior are blocked by naloxone. 25th Annu. Conf. Reprod. Behav., East Lansing, MI.
61. Rubinstein M., Mogil J.F., Japón M., Chan E.C., Allen R.G., Low M.J. Absence of opioid stress-induced analgesia in mice lacking β-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA. 93:1996;3995-4000.
62. Schedlowski M., Flüge T., Richter S., Tewes U., Schmidt R.E., Wagner T.O.F. β-endorphin, but not substance P, is increased by acute stress in humans. Psychoneuroendocrinology. 20:1995;103-110.
63. Schoffelmeer A.N.M., Wardeh G., Hogenboom F., Mulder A.H. β-endorphin: A highly selective endogenous opioid agonist for presynaptic mu opioid receptors. J. Pharmacol. Exp. Ther. 258:1991;237-242.
64. A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur. J. Pharmacol. 249:1993;341-351.
65. Soubrié P., Jobert A., Thiebot M.H. Differential effects of naloxone against the diazepam-induced release of behavior in rats in three aversive situations. Psychopharmacology. 69:1980;101-105.
66. Stein L., Wise C.D., Belluzzi J.D. Effects of benzodiazepines on central serotonergic mechanisms. Adv. Biochem. Psychopharmacol. 14:1975;29-44.
67. Suzuki T., Yoshiike M., Mizoguchi J., Kamei J., Misawa M., Nagase H. Blockade of δ-opioid receptors prevents morphine-induced place preference in mice. Jpn. J. Pharmacol. 66:1994;131-137.
68. Takemori A.E., Ho B.Y., Naeseth J.S., Porthogese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246:1988;255-258.
69. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:1993;463-469.
70. Tsuda M., Suzuki T., Misawa M., Nagase H. Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur. J. Pharmacol. 307:1996;7-14.
71. Ward S.J., Porthogese P.S., Takemori A.E. Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J. Pharmacol. Exp. Ther. 220:1982;494-498.
72. Westenberg H.G.M., den Boer J.A. The neuropharmacology of anxiety: A review on the role of serotonin. den Boer J.A., Sitsen J.M.A. Handbook of Depression and Anxiety: A Biological Approach. 1994;405-446 Marcel Dekker, New York.
73. Wise C.D., Berger B., Stein L. Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain. Science. 177:1972;180-183.
74. Wright I.K., Upton N., Marsden C.A. Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology. 109:1992;338-346.
75. Wüster M., Duka T., Herz A. Diazepam effects on striatal met-enkephalin levels following long-term pharmacological manipulations. Neuropharmacology. 19:1980;501-505.
76. Yamada K., Nabeshima T. Stress-induced behavioral responses and multiple opioid systems in the brain. Behav. Brain Res. 67:1995;133-145.
77. Yoshioka M., Matsumoto M., Togashi H., Smith C.B., Saito H. Opioid receptor regulation of 5-hydroxytryptamine release from the hippocampus measured by in vivo microdialysis. Brain Res. 613:1993;74-79.
78. Yoshioka M., Matsumoto M., Togashi H., Saito H. Effects of conditioned fear stress on 5-HT release in the rat prefrontal cortex. Pharmacol. Biochem. Behav. 51:1995;515-519.